Prostate Cancer

Latest News


Educated Patient Resource Guide

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Educated Patient Resource Guide

A clinical trial will test a radiation regimen designed to preserve sexual function in men being treated for prostate cancer.

The FDA has granted the PARP inhibitor Rubraca (rucaparib) a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer (mCRPC) following at least one androgen receptor–directed therapy and taxane-based chemotherapy.

Prostate cancer is one of the most common cancers in males, with about one man in nine to be diagnosed during his lifetime, according to the American Cancer Society.

After his own journey with prostate cancer, radio and TV personality Ed Randall used his extensive connections throughout professional sports to spread awareness about prostate cancer through his nonprofit organization Fans for the Cure.

What do Bill Nye the Science Guy, fashion designer Michael Kors and one very special prostate cancer advocate all have in common? Blue jackets, a runway and the ultimate goal of raising awareness for prostate cancer.